Avelumab and Merkel Cell Carcinoma: Examining the Evidence on Risk and Causation

From General Health to Occupational Exposure Concerns

For decades, mass production environments have drawn on general health and science information to inform workplace wellness initiatives, often emphasizing broad lifestyle factors such as diet, exercise, and cardiovascular risk reduction. This legacy approach, grounded in large-scale population studies, has provided a useful foundation for employee health programs. However, as industrial processes evolve and chemical exposures become more complex, the limitations of a purely general health framework become apparent. The transition from population-level prevention to occupation-specific risk assessment requires a shift in focus—from universal health advice to targeted inquiry into the potential consequences of specific workplace exposures. In particular, the growing body of pharmacovigilance and post-marketing surveillance data has raised questions about the relationship between therapeutic agents and subsequent disease risk. This prompts a natural pivot: from the general health context of chronic disease prevention to a more focused examination of occupational exposure concerns. Specifically, the question of whether exposure to certain biologic agents in manufacturing or healthcare settings may be associated with elevated risk of rare malignancies, such as Merkel cell carcinoma, warrants careful consideration. This transition acknowledges that while general health information remains valuable, the nuances of occupational exposure demand a more precise analytical lens.

Avelumab: Mechanism and Therapeutic Role in Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1) and functions as an immune checkpoint inhibitor (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). Approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is thus the first therapeutic agent specifically approved for this indication, and is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyomavirus; approximately 80% of cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/35877101/). The incidence rate of MCC is increasing, and it is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab, offer durable responses and significant clinical benefit, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Additionally, 50% of patients do not respond or develop immune-related adverse events due to diverse mechanisms, such as down-regulation of MHC complexes or the induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/).

Causation vs. Treatment: Clarifying the Relationship Between Avelumab and MCC

The mechanistic pathways linking avelumab to Merkel cell carcinoma are primarily therapeutic rather than causative. Avelumab is used to treat MCC, not to cause it. The drug functions by blocking PD-L1, thereby enhancing the immune system's ability to recognize and attack cancer cells. In patients with MCC, avelumab has demonstrated efficacy in inducing tumor regression. However, for patients who are refractory to avelumab, treatment options are limited. Studies have investigated the use of combined ipilimumab and nivolumab in avelumab-refractory MCC. In a retrospective study at three different sites in Germany, clinical and molecular data of patients with metastatic MCC refractory to avelumab and later treated with combined ipilimumab/nivolumab were collected. Three out of five patients responded to combined therapy according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG similarly reported on ipilimumab plus nivolumab in avelumab-refractory MCC (https://pubmed.ncbi.nlm.nih.gov/36450381/). Another retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC noted that despite advances in systemic therapy, about 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Regarding causation-related considerations for affected patients, it is important to clarify that avelumab is not a cause of Merkel cell carcinoma but rather a treatment for it. The drug is indicated for metastatic MCC, and its use is based on evidence of efficacy in this patient population. The adequacy of warnings regarding avelumab and MCC is reflected in the drug's prescribing information, which includes details on its approved indication and potential adverse effects. Immune-related adverse events are a known risk of immune checkpoint inhibitors, including avelumab, and can affect various organ systems. The timeline between exposure and documented harm in the context of avelumab and MCC is typically measured in terms of treatment response or progression rather than causation of the disease itself. Patients receiving avelumab for MCC may experience immune-related adverse events at any time during treatment, and the drug's efficacy is assessed over weeks to months.

Evidence Summary and Risk Context

In summary, avelumab is an established treatment for metastatic Merkel cell carcinoma, with a well-documented efficacy profile based on clinical trials. The drug does not cause MCC but is used to manage the disease. For patients who do not respond to avelumab, alternative immune checkpoint inhibitor combinations may be considered. The evidence supports the role of avelumab as a therapeutic agent in MCC, with appropriate warnings regarding its use and potential adverse effects. References: https://pubmed.ncbi.nlm.nih.gov/33439294/, https://pubmed.ncbi.nlm.nih.gov/29799096/, https://pubmed.ncbi.nlm.nih.gov/36450381/, https://pubmed.ncbi.nlm.nih.gov/35877101/, https://pubmed.ncbi.nlm.nih.gov/34445385/.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, avelumab is a treatment for Merkel cell carcinoma (MCC), not a cause. It is an immune checkpoint inhibitor that blocks PD-L1 to help the immune system attack cancer cells. The drug is approved for metastatic MCC based on clinical trials showing efficacy.

What is the evidence for avelumab's efficacy in Merkel cell carcinoma?

The JAVELIN Merkel 200 trial showed confirmed objective responses in about one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Response rates to PD-1/PD-L1 inhibition in MCC can reach up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/).

What are the risks of avelumab treatment?

Immune-related adverse events are a known risk of immune checkpoint inhibitors, including avelumab, and can affect various organ systems. About 50% of patients with advanced MCC may not respond or may progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.